BioNTech (22UA GY / BNTX) FY 2025 (EUR): Revenue 2.87bln (exp. 2.72bln), EPS -4.70 (exp. -3.08); outlook: Revenue 2-2.3bln (exp. 2.75bln)
Context
BioNTech's FY 2025 earnings report shows a revenue beat against expectations, although its EPS fell short of estimates, indicating potential concerns about profitability. The forward guidance for revenue is notably lower than expected, which may dampen sentiment and put pressure on the stock as the market assesses the implications for growth going forward.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#EU SESSION#EUROPEAN EQUITIES